In order to determine why mice with Ptprd loss had a faster onset of clinical signs, we first examined whether mice with Ptprd and Cdkn2a deletion had a greater number of tumor types compared to mice with Cdkn2a deletion alone. This evidence concerns the gene PTPRD and neoplasm.